Encoded Therapeutics Inc.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
$275MSeries F
ParticipantRI
RTW Investments
Activity from announced rounds
Activity in this selectionOct 25, 2026 · Biotech · Jan 1, 2026
RTW Investments is the investment manager named in Amani and Encoded financing histories.
Recorded funding activity
Amani develops combination medicines for neuropsychiatric disorders. Encoded develops gene-regulation therapies for neurological disease. The histories refer to the manager rather than a specified RTW fund.
- Rounds participated in
- 3
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $300M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionAmani Therapeutics
Biotechnology company developing combination medicines for serious neuropsychiatric disorders.
$25MSeries A
Role not disclosedCorxel Pharmaceuticals
Corxel Pharmaceuticals develops clinical-stage medicines for cardiometabolic diseases, including obesity, diabetes, stroke and hypertension.
≤$287MSeries D1
Participant